The 6-month target lesion primary patency (TLPP)1 and access circuit primary patency (ACPP)2 for patients in the arteriovenous fistula (AVF) cohort were 92.7% and 76.7%, respectivelyThe real-world patency results observed in the WRAP Global Registry are higher than the patency results from the WRAPSODY Arteriovenous Access Efficacy (WAVE) pivotal trial, validating the already favorable performance of the device SOUTH JORDAN, Utah, Nov. 05, 2026 (GLOBE NEWSWIRE) — Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader of healthcare technology, today announced results from the AVF cohort of the WRAPSODY (WRAP) Global registry. Clinical data were presented during the New Innovations, Trials, Techniques & Devices session on Saturday, October 31, 2026, at the Controversies in Dialysis Access (CiDA)* conference held in Washington, DC. Hemodialysis is a life-sustaining therapy for patients diagnosed with advanced kidney disease. For many patients, the creation and long-term maintenance of an AVF is essential for ongoing access to blood vessels (vascular access). However, impairments in and around the fistula due to progressive narrowing (stenosis) and/or blockage (occlusion) are inevitable for some patients. These obstructions can interfere with a patient’s ability to receive hemodialysis, require repeated interventions, and may result in life-threatening consequences. The WRAPSODY™ Cell-Impermeable Endoprosthesis (CIE) was developed to restore functionality in vascular access in patients who experience stenosis/occlusion. The device’s favorable performance has been documented in the clinical trial setting.3–6 Real-world data provide insight into how a medical device performs when used in routine clinical practice, outside the controlled setting of a traditional clinical trial. The WRAP Global registry is an international, multicenter, prospective study designed to evaluate the performance of the WRAPSODY CIE in real-world clinical practice through 24 months following device placement. A total of 237 patients were enrolled in the AVF cohort across 31 sites in nine countries. The 6-month TLPP1 was 92.7%, and the 6-month ACPP2 was 76.7%. These findings align with the patency rates observed in the AVF cohort in the WAVE pivotal trial (6-month TLPP: 89.8%; 6-month ACPP: 72.8%).4 “These are the results physicians have been waiting for,” said Panagiotis M. Kitrou, MD, MSc, PhD, EBIR, FCIRSE, Co-Global Principal Investigator of the WRAP Global registry, Associate Professor of Interventional Radiology at Patras University Hospital in Patras, Greece, and a clinical consultant to Merit Medical. “Real-world insight regarding the patency of WRAPSODY provides an important benchmark for this patient population.” “The promising patency outcomes from the WRAP Global registry are likely to improve physician confidence in the clinical benefits associated with WRAPSODY and help to further optimize patient care,” said Dheeraj K. Rajan, MD, Co-Global Principal Investigator of the WRAP Global registry, Professor and Division Head in the Department of Vascular Interventional Radiology at the University of Toronto in Toronto, Canada, who also serves as a clinical advisor to Merit Medical. “These results reinforce our commitment to building a comprehensive body of clinical evidence for WRAPSODY, which includes both rigorous clinical trials and real-world practice,” said Martha G. Aronson, Merit’s President and Chief Executive Officer. “Helping physicians maintain vascular access and reduce the burden associated with repeat interventions is central to what we are working to achieve for patients receiving hemodialysis worldwide.” The WRAPSODY CIE received premarket approval from the U.S. Food and Drug Administration (FDA) in December 2024 and was approved by Health Canada in April 2025. In January 2025, Merit began commercialization of the device in the United States. The device previously received the Conformité Européenne (CE) Mark for commercial use in the European Union and is available in Brazil. In addition to the WRAP Global registry, real-world clinical outcomes of the WRAPSODY CIE are being evaluated in the WRAP North America registry, which is designed to enroll up to 250 patients in the United States and Canada. For additional information on Merit’s WRAP North America registry, please visit: https://clinicaltrials.gov/study/NCT06807099. Merit believes that the collective data from the WAVE trial, the WRAP North America registry, and the WRAP Global registry will generate evidence on the largest cohort of patients for a single indication in dialysis access to date. For more information on the WRAPSODY CIE within the United States, please visit: https://www.merit.com/product/wrapsody-cie/. For information on the device outside of the United States, please visit: https://www.merit.com/product/merit-wrapsody/. Cautionary statement regarding forward-looking statements Any forward-looking statements set forth in this release are subject to risks and uncertainties such as those described in Merit’s filings with the U. S. Securities and Exchange Commission (“SEC”). For discussion of the risks and uncertainties which may affect Merit’s business, operations and financial condition, see Part I, Item 1A, “Risk Factors” in Merit’s Annual Report on Form 10-K for the year ended December 31, 2025 filed with the SEC, which Merit updated in Part II, Item 1A, “Risk Factors” in Merit’s Quarterly Reports on Form 10-Q for the quarters ended March 31, 2026, June 30, 2026 and September 30, 2026, which Merit filed with the SEC. Actual results will likely differ, and may differ materially, from anticipated results. ABOUT MERIT Founded in 1987, Merit Medical Systems, Inc. is engaged in the development, manufacture, and distribution of proprietary medical devices used in interventional, diagnostic, and therapeutic procedures, particularly in cardiology, radiology, oncology, critical care, and endoscopy. Merit serves customers worldwide with a domestic and international sales force and clinical support team totaling approximately 900 individuals. Merit employs approximately 7,500 people worldwide. *ABOUT CiDA Controversies in Dialysis Access (CiDA) is a leading multidisciplinary educational forum dedicated to advancing the care of patients requiring dialysis access. Established in 2003, CiDA brings together vascular surgeons, interventional radiologists, nephrologists, and other healthcare professionals to examine current challenges, emerging technologies, clinical research, and evolving approaches to dialysis access management. Through expert presentations, interactive debates, case discussions, and hands-on education, CiDA promotes collaboration and the exchange of knowledge to improve patient care. For more information, visit www.dialysiscontroversies.org. TRADEMARKS Unless noted otherwise, trademarks and registered trademarks used in this release are the property of Merit Medical Systems, Inc., its subsidiaries, or its licensors. CONTACTSPR/Media InquiriesSarah ComstockMerit Medical+1-801-432-2864 | sarah.comstock@merit.com INVESTOR INQUIRIESMike Piccinino, CFA, IRCWestwicke – ICR+1-443-213-0509 | mike.piccinino@westwicke.com TLPP (primary effectiveness endpoint) was defined as the proportion of patients who did not require an intervention due to clinically driven target lesion revascularization or target lesion thrombosis.ACPP (a secondary effectiveness endpoint) was defined as the proportion of patients without loss of vascular access anywhere within the circuit from the time of their initial treatment to the need for reintervention or abandonment of vascular access.Gilbert et al. 2021. “First Clinical Results of the Merit WRAPSODY™ Cell-Impermeable Endoprosthesis for Treatment of Access Circuit Stenosis in Haemodialysis Patients.” Cardiovasc Interv Radiol 44, no. 12 (Dec): 1903–13. doi: 10.1007/s00270-021-02953-8.Razavi et al. 2025. “Six-Month Safety and Efficacy Outcomes from the Randomized-Controlled Arm of the WRAPSODY Arteriovenous Access Efficacy (WAVE) Trial.” Kidney Int 107, no. 4 (Apr): 740–50. doi: 10.1016/j.kint.2025.01.006.Razavi et al. 2026. “One-Year Clinical Outcomes from the Randomized-Controlled Arm of the WRAPSODY Arteriovenous Access Efficacy (WAVE) Trial.” J Vasc Interv Radiol 37, no. 6 (Jun): 108593. Online ahead of print. doi: 10.1016/j.jvir.2026.108593.Razavi et al. 2026. “Safety and Effectiveness of the Wrapsody Cell-Impermeable Endoprosthesis to Treat Dysfunctional Arteriovenous Grafts: Results from the Nonrandomized Arm of the WAVE Trial.” J Vasc Interv Radiol 37, no. 6 (Jun): 108594. Online ahead of print. doi: 10.1016/j.jvir.2026.108594.
Tag: Dialysis
Humacyte’s Bioengineered Blood Vessel Outperforms the Standard of Care for Women on Dialysis in Phase 3 Results Presented at the Society for Vascular Surgery Vascular Annual Meeting
– Positive results from the V012 Phase 3 study were presented at the Society for Vascular Surgery’s Vascular Annual Meeting in Boston –
Phraxis Announces First-Ever Commercial Case of EndoForce™ Anastomotic Connector at Spartanburg Regional Medical Center
MINNEAPOLIS, Aug. 29, 2025 /PRNewswire/ — Phraxis, Inc., a leader in vascular access innovation, today announced the successful completion of the first commercial case using the EndoForce™ Anastomotic Connector, marking a historic milestone in the treatment of dialysis patients worldwide….
Merit Medical’s WRAPSODY WAVE Trial Exceeds Performance Goals for Arteriovenous Graft (AVG) Patients
WRAPSODY achieves 82% target lesion primary patency at six months in the single-arm cohort of the US pivotal trial WRAPSODY achieves 82% target lesion primary patency at six months in the single-arm cohort of the US pivotal trial
Xeltis receives IDE approval from FDA for initiation of US pivotal trial for aXess™, its restorative vascular access conduit
aXess is a restorative arteriovenous dialysis conduit which allows vascular access for hemodialysis through the creation of a new, permanent, living vessel
EINDHOVEN, The Netherlands, June 13, 2024 /PRNewswire/ — Xeltis, a leading developer of transformative implants that enable the natural creation of living and long-lasting vessels, announces that it has gained approval from the US Food and Drug Administration (FDA) for an Investigational Device Exemption (IDE) submission to begin enrolling patients into a pivotal study for aXess.
aXess is a restorative conduit that enables the creation of a new, permanent, living vessel for hemodialysis vascular access, combining the safety and patency of an arteriovenous fistula (AVF), with the speed to treatment of an arteriovenous graft (AVG). The aXess vascular access conduit offers an improved dialysis patient experience and avoids the frequent reinterventions and complications, such as infections, faced by many renal disease patients.
Xeltis’ groundbreaking implants platform is an important development in vascular replacement technology as, over time, its implants are gradually replaced by the patients’ own living healthy tissue. Xeltis’ novel technology has already treated over 100 patients across different clinical trials.
Eliane Schutte, Chief Executive Officer, Xeltis commented: “We have already shown outstanding 12-month data from our first-in-human study in Europe and are looking forward to starting this pivotal trial in the US. We are very proud of the potential for aXess to transform the field of vascular access by stopping the cycle of interventions and infections and bringing our unique restorative solution to hemodialysis patients worldwide.”
Paulo Neves, Chief Medical Officer, Xeltis said: “Our focus is on improving the outcomes for patients on dialysis. aXess offers this potential through its avoidance of the reinterventions and complications associated with other vascular access solutions. This pivotal study is important in assessing and demonstrating this and marks a significant milestone in our clinical strategy in the US.”
The US-based pivotal trial follows strong 12-month data from the first-in-human trial in Europe in comparison to hemodialysis vascular access solutions. aXess is also undergoing an EU pivotal trial, recruiting up to 110 patients in nine EU countries.
About XeltisXeltis is a medtech company developing transformative implants that enable the natural creation of living and long-lasting vessels. Xeltis seeks to address the limitations of currently available options for the millions of people requiring hemodialysis access grafts or cardiovascular replacements every year. The Company’s proprietary endogenous tissue restoration (ETR) platform utilizes an advanced polymer implant which regenerates the patient’s own tissue before gradually being absorbed and leaving new, living, and long-lasting vessels in place. Xeltis’ most advanced product currently under clinical development is aXess™, an implantable blood vessel for hemodialysis vascular access. Xeltis’ groundbreaking technology has high potential to be applied to other major vascular and cardiovascular diseases.
Xeltis is based in The Netherlands and the USA. Its investors include DaVita Venture Group, EQT Life Sciences, Kurma Partners, VI Partners, Ysios Capital, Grand Pharma Group, the European Innovation Council and Invest-NL, in addition to other public and private investors.
About aXessaXess is a restorative conduit which enables the creation of a new, permanent, living vessel for hemodialysis vascular access. It combines the safety and patency of a fistula with the speed to treatment of an AV graft. The aXess vascular access conduit offers an improved dialysis patient experience and avoids the frequent reinterventions and complications, such as infections, faced by renal disease patients.
A first-in-human trial of aXess demonstrated a significant improvement in performance compared to hemodialysis vascular access solutions. A pivotal trial of aXess is currently enrolling up to 110 patients in nine EU countries.
Go to axesspivotal.com for more details.
SOURCE Xeltis
Bay Area’s Outset Medical Banks $76.5 Million for Innovative Dialysis Technology
SAN JOSE, Calif.–(BUSINESS WIRE)–Outset Medical, a commercial-stage company delivering first-of-its-kind technology into the $13 billion global dialysis market, today announced $76.5 million in Series C equity funding. A new investor, funds advised by T. Rowe Price Associates, Inc., led the round, which also included participation from existing investors Fidelity Management […]



